Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL‐2 receptor blockade in an islet transplant recipient
- 14 September 2007
- journal article
- case report
- Published by Wiley in Clinical Transplantation
- Vol. 22 (2) , 250-253
Abstract
Abstract: The utilization of dual maintenance therapy with tacrolimus and sirolimus (the Edmonton protocol) has been widely adopted as standard immunosuppression for islet cell transplantation. This immunosuppression regimen has numerous toxicities including renal dysfunction, anemia, and recurrent aphthous ulcers. We present a case of a 63‐yr‐old Caucasian female who received an isolated islet transplant. Over the first six months post‐transplant, the patient developed severe anemia, intractable aphthous ulcers, and renal dysfunction. Islet transplant function was excellent and the patient is insulin‐independent since the end of the second month post‐transplant. However, because of the above toxicities, a decision was made to change her immunosuppression regimen eight months post‐transplant to low dose tacrolimus, mycophenolate mofetil, and a monthly maintenance infusion of daclizumab. Since then, her aphthous ulcers have disappeared, renal function has improved, and islet cell function remains stable.Keywords
This publication has 12 references indexed in Scilit:
- Pretransplant HLA Antibodies Are Associated with Reduced Graft Survival After Clinical Islet TransplantationAmerican Journal of Transplantation, 2007
- Changes in Renal Function after Clinical Islet Transplantation: Four-Year Observational StudyAmerican Journal of Transplantation, 2007
- International Trial of the Edmonton Protocol for Islet TransplantationNew England Journal of Medicine, 2006
- A Significant Role for Histocompatibility in Human Islet TransplantationTransplantation, 2006
- Immunosuppression and Procedure-Related Complications in 26 Patients with Type 1 Diabetes Mellitus Receiving Allogeneic Islet Cell TransplantationTransplantation, 2005
- A Prospective, Randomized Trial of Tacrolimus in Combination with Sirolimus or Mycophenolate Mofetil in Kidney Transplantation: Results at 1 YearTransplantation, 2005
- Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1Transplantation, 2005
- Benefit-Risk Assessment of Sirolimus in Renal TransplantationDrug Safety, 2005
- Effect of Sirolimus Withdrawal in Patients with Deteriorating Renal FunctionAmerican Journal of Transplantation, 2004
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003